An Extensive-stage Small-cell Lung Cancer Case With Preexisting Lambert-Eaton Myasthenic Syndrome Successfully Treated With an Immune Checkpoint Inhibitor

被引：7

作者：

Sakaguchi, Tadashi ^{[1
]}

Kokubo, Yasumasa ^{[2
]}

Furuhashi, Kazuki ^{[1
]}

Nakamura, Yuki ^{[1
]}

Suzuki, Yuta ^{[1
]}

Ito, Kentaro ^{[1
]}

Fujiwara, Kentaro ^{[1
]}

Nishii, Yoichi ^{[1
]}

Taguchi, Osamu ^{[1
]}

Hataji, Osamu ^{[1
]}

机构：

[1] Matsusaka Municipal Hosp, Resp Ctr, 1550 Tonomachi, Matsusaka, Mie 5150073, Japan

[2] Mie Univ, Grad Sch Reg Innovat Studies, Kii ALS PDC Res Ctr, Tsu, Mie, Japan

来源：

CLINICAL LUNG CANCER | 2022年 / 23卷 / 03期

关键词：

active autoimmune disease; Anti-P/Q-type voltage gated calcium channel antibody; paraneoplastic syndrome; PD-L1; inhibitor; waxing phenomenon; DISEASE;

D O I：

10.1016/j.cllc.2021.09.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

• Immune checkpoint inhibitor (ICI) therapy could exacerbate preexisting active autoimmune diseases (AIDs), and the presence of preexisting AIDs might be associated with a greater risk of developing new immune-related adverse events (irAEs). • The safety of ICIs for patients with Lambert-Eaton myasthenic syndrome (LEMS), a neuromuscular autoimmune disease known as a paraneoplastic syndrome mainly associated with small-cell lung cancer (SCLC), is fully unknown. • We experienced an extensive-stage (ES)-SCLC patient with LEMS successfully treated with chemotherapy in combination with ICI without a flare-up of LEMS. • Phase III trials have shown that ICIs in combination with platinum doublet therapy significantly improved the overall survival of patients with ES-SCLC in first-line settings, therefore, patients diagnosed with ES-SCLC with the complication of LEMS have the widespread opportunity to receive ICIs as standard care. This report suggests that treatment using ICIs may be a treatment option to consider for ES-SCLC patients with LEMS. © 2021 The Authors

引用

页码：E273 / E275

页数：3

共 9 条

[1] Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer [J].

Agrawal, Kavita ;

Agrawal, Nirav .

CASE REPORTS IN NEUROLOGICAL MEDICINE, 2019, 2019

[2] Immunoglobulins to mitigate paraneoplastic Lambert Eaton Myasthenic Syndrome under checkpoint inhibition in Merkel cell carcinoma [J].

Dohrn, Maike F. ;

Schoene, Ulrike ;

Kueppers, Charlotte ;

Christen, Deborah ;

Schulz, Joerg B. ;

Gess, Burkhard ;

Tauber, Simone .

NEUROLOGICAL RESEARCH AND PRACTICE, 2020, 2 (01)

[3] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].

Horn, L. ;

Mansfield, A. S. ;

Szczesna, A. ;

Havel, L. ;

Krzakowski, M. ;

Hochmair, M. J. ;

Huemer, F. ;

Losonczy, G. ;

Johnson, M. L. ;

Nishio, M. ;

Reck, M. ;

Mok, T. ;

Lam, S. ;

Shames, D. S. ;

Liu, J. ;

Ding, B. ;

Lopez-Chavez, A. ;

Kabbinavar, F. ;

Lin, W. ;

Sandler, A. ;

Liu, S. V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229

[4] Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads [J].

Meriney, Stephen D. ;

Tarr, Tyler B. ;

Ojala, Kristine S. ;

Wu, Man ;

Li, Yizhi ;

Lacomis, David ;

Garcia-Ocana, Adolfo ;

Liang, Mary ;

Valdomir, Guillermo ;

Wipf, Peter .

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2018, 1412 (01) :73-81

[5] Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer [J].

Nakatani, Yuki ;

Tanaka, Natsuki ;

Enami, Tomomi ;

Minami, Seigo ;

Okazaki, Tomoko ;

Komuta, Kiyoshi .

CASE REPORTS IN NEUROLOGY, 2018, 10 (03) :346-352

[6] Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J].

Paz-Ares, Luis ;

Dvorkin, Mikhail ;

Chen, Yuanbin ;

Reinmuth, Niels ;

Hotta, Katsuyuki ;

Trukhin, Dmytro ;

Statsenko, Galina ;

Hochmair, Maximilian J. ;

Ozguroglu, Mustafa ;

Ji, Jun Ho ;

Voitko, Oleksandr ;

Poltoratskiy, Artem ;

Ponce, Santiago ;

Verderame, Francesco ;

Havel, Libor ;

Bondarenko, Igor ;

Kazarnowicz, Andrzej ;

Losonczy, Gyorgy ;

Conev, Nikolay V. ;

Armstrong, Jon ;

Byrne, Natalie ;

Shire, Norah ;

Jiang, Haiyi ;

Goldman, Jonathan W. ;

Batagelj, Emilio ;

Casarini, Ignacio ;

Pastor, Anea Viviana ;

Sena, Susana Noemi ;

Zarba, Juan Jose ;

Burghuber, Otto ;

Hartl, Sylvia ;

Hochmair, Maximilian J. ;

Lamprecht, Bernd ;

Studnicka, Michael ;

Schlittler, Luis Alberto ;

de Oliveira, Fabricio Augusto Martinelli ;

Calabrich, Aknar ;

Girotto, Gustavo Colagiovanni ;

Dos Reis, Peo ;

Gorini, Carlos Fausto Nino ;

De Marchi, Peo Rafael Martins ;

Baldotto, Clarissa Serodio da Rocha ;

Sette, Claudia ;

Zukin, Mauro ;

Conev, Nikolay V. ;

Dudov, Assen ;

Ilieva, Rumyana ;

Koynov, Krassimir ;

Krasteva, Rositsa ;

Tonev, Ivan .

LANCET, 2019, 394 (10212) :1929-1939

[7] Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies [J].

Xie, Wenhui ;

Huang, Hong ;

Xiao, Shiyu ;

Fan, Yong ;

Deng, Xuerong ;

Zhang, Zhuoli .

AUTOIMMUNITY REVIEWS, 2020, 19 (12)

[8] CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model [J].

Yshii, Lidia M. ;

Gebauer, Christina M. ;

Pignolet, Beatrice ;

Maure, Emilie ;

Queriault, Clemence ;

Pierau, Mandy ;

Saito, Hiromitsu ;

Suzuki, Noboru ;

Brunner-Weinzierl, Monika ;

Bauer, Jan ;

Liblau, Roland .

BRAIN, 2016, 139 :2923-2934

[9] Functions of Immune Checkpoint Molecules Beyond Immune Evasion [J].

Zhang, Yaping ;

Zheng, Junke .

REGULATION OF CANCER IMMUNE CHECKPOINTS: MOLECULAR AND CELLULAR MECHANISMS AND THERAPY, 2020, 1248 :201-226

← 1 →